TORONTO, ONTARIO: - Data Presented at the American Society of Nephrology Supports Spectral's EUPHRATES Trial Design - Toraymyxin(TM) Treatment Resulted in an Approximate 25% Relative Reduction in Mortality
...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.